While pharmacologic agents have a proved effective in children with Attention-deficit/hyperactivity disorder (ADHD), some children have suboptimal response to a single pharmacologic agent.
A recent study by Dr. Timothy E. Wilens and colleagues, published in the January 2012 issue of the Journal of the American Academy of Child and Adolescent Psychiatry (JAACAP), is the first randomized placebo-controlled trial designed to assess efficacy and safety of guanfacine extended release (GXR) as an adjunct to psychostimulants in children and adolescents diagnosed with ADHD who had a suboptimal response to a psychostimulant alone.
Attention Deficit Hyperactivity Disorder (ADHD)
Attention Deficit Hyperactivity Disorder (ADHD) is a neurobiological disorder that affects normal behavior and impairs the ability to concentrate.
Advertisement
As reported in the article "A Controlled Trial of Extended-release Guanfacine and Psychostimulants for Attention-deficit/hyperactivity disorder," Wilens and colleagues conducted a nine week multicenter, double-blind, placebo-controlled, dose-optimization study, with participants in 59 study sites who continued their stable dose of psychostimulant given in the morning and were randomized to receive GXR in the morning, GXR in the evening, or placebo.
For both morning and evening administration of GXR, subjects receiving GXR plus a psychostimulant showed significantly greater improvement from baseline to endpoint, as measured by the ADHD-Rating Scale IV total score, compared with subjects receiving placebo plus a psychostimulant. In particular, the inattention subscale rating and the hyperactivity/ impulsivity subscales of the ADHD-RS-IV showed significantly greater improvements from baseline in subjects receiving GXR with a psychostimulant compared with subjects receiving placebo plus psychostimulant. Significant benefits of adjunctive administration were observed whether GXR was administered in the morning or evening. No new safety signals emerged after adjunctive administration of GXR with psychostimulants compared with psychostimulants alone.
![Quiz on ADHD]( "Quiz on ADHD")
Attention Deficit/Hyperactivity Disorder (AD/HD, generally abbreviated as ADHD) is considered a "neurobehavioral developmental disorder". To know what this definition means and what the causes, symptoms and treatment for ADD are; give our ADHD quiz your best shot.
Reflecting on their research findings, Wilens and colleagues stated, "The results of this study support the hypothesis that adjunctive administration of the selective alpha2A-adrenoceptoragonist, GXR, to a psychostimulant in subjects with suboptimal response to psychostimulants reduces ADHD symptoms over placebo with a psychostimulant."
Source: Eurekalert
Quiz on ADHD
Attention Deficit/Hyperactivity Disorder (AD/HD, generally abbreviated as ADHD) is considered a "neurobehavioral developmental disorder". To know what this definition means and what the causes, symptoms and treatment for ADD are; give our ADHD quiz your best shot.
Advertisement
Reflecting on their research findings, Wilens and colleagues stated, "The results of this study support the hypothesis that adjunctive administration of the selective alpha2A-adrenoceptoragonist, GXR, to a psychostimulant in subjects with suboptimal response to psychostimulants reduces ADHD symptoms over placebo with a psychostimulant."
Source: Eurekalert
Restricted Diet Devoid of Additives May Benefit Children With Attention Deficit Hyperactivity Disorder (ADHD)
As there is no evidence for the effectiveness of IgG blood tests, researchers wanted to study the link between diet and behavior among children with ADHD.
Advertisement
 Kids With ADHD Learning Disability - Handling With CareChildren with ADHD develop learning disability which can be treated with the intervention of medical practitioners and Occupational therapists | Advertisement
|
Advertisement
